Open Forum Infectious Diseases · 2018 · 18 citations · 8 references
MedicinePharmacologyPharmacotherapyImmunopharmacologyImmunotherapyMedical MicrobiologyBacterial InfectionsImmunomodulatory Drug TherapySkin InfectionsSoft Tissue InfectionsB-cell Malignancy TherapyBruton Tyrosine KinaseBruton's Tyrosine Kinase InhibitorsOpportunistic Cutaneous InfectionsOpportunistic Skin InfectionsSkin Infection TreatmentTyrosine Kinase InhibitionTyrosine Kinase Receptors
Abstract Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of Mycobacterium chelonae skin and soft tissue infection in a patient receiving ibrutinib and recount the challenges in treating this infection.
8
R. J. Wallace, Barbara A. Brown, G O Onyi · The Journal of Infectious Diseases · 1992 · 361 citations
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
David Ghez, Anne Calleja, Caroline Protin et al. · Blood · 2018 · 296 citations · Full text
Georgios Chamilos, Michail S. Lionakis, Dimitrios P. Kontoyiannis · Clinical Infectious Diseases · 2017 · 265 citations · Full text
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Tilly Varughese, Ying Taur, Nina Cohen et al. · Clinical Infectious Diseases · 2018 · 264 citations · Full text